Jordyn Sava is an editor for Targeted Oncology.
Robotic Surgery Can Effectively Treat High-Risk EC After Prior Hysterectomy
January 30th 2024Robotic peritoneal mesometrial resection with targeted or systemic lymphadenectomy demonstrated feasibility with acceptable complication rates in intermediate/high-risk endometrial cancer requiring second surgery after prior hysterectomy.
Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC
January 30th 2024In an interview with Targeted Oncology, Thomas Powles, MD, MBBS, MRCP, discussed the impressive performance of enfortumab vedotin plus pembrolizumab for the treatment of locally advanced or metastatic urothelial carcinoma, as seen in the EV-302 trial.
First-Line Nivolumab Plus Ipilimumab Demonstrates Superior PFS in mCRC
January 20th 2024Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
Assal Explores the Current Landscape and Future Prospects of BMSCT
January 19th 2024In an interview with Targeted Oncology, Amer Assal, MD, provided insights into the risks and complications associated with stem cell transplants, emphasizing the importance of risk stratification and preventive measures.
Wave of Innovation Reshapes Treatments for Genitourinary Cancers
January 18th 2024Francesca Jackson-Spence, PhD, and Matthew Young, MD, delved into the major advances in genitourinary cancer treatment, including breakthroughs in immunotherapy, targeted therapies, and early detection that offer new hope for patients.